Loading, Please Wait...
PHILADELPHIA, June 05, 2019 (GLOBE NEWSWIRE) -- The 11th annual Dealmakers’ Intentions Study from Syneos Health Consulting, an industry-leading biopharmaceutical management consulting firm, indicates that there will be an acceleration in dealmaking across all deal types. The 2019 survey results indicate that buyers appear more willing to accept risk associated with opportunities in the early development and rare disease categories.
The study, released during a Super Session at the BIO International Convention in Philadelphia, provides a review of biopharmaceutical dealmakers’ intentions around licensing and acquisitions for the next 12 months, identifying areas of greatest opportunities for buyers and sellers. For the first time, the study also includes new data on buyer and seller interest in rare disease opportunities.
“In this healthy dealmaking environment, buyers are intensely focused on finding assets that are the best strategic fit for their business and are being heavily influenced by the probability of regulatory and technical success,” said Neel Patel, Senior Managing Director, Commercial Advisory Group, Syneos Health Consulting. “Sellers can take advantage of these expanding dealmaking options by clearly understanding and communicating their commercial value and using creative dealmaking options to avoid financial disagreements.”
Key findings include:
M&A Landscape Continues Bullish Run with the Potential to Reach $200-$250 Billion in 2019
Buyers Appear to Be Willing to Accept More Risk in Early Development and Rare Disease Categories; Oncology Remains a Hot Spot
Orphan Drug Market is Becoming a Cornerstone for Dealmaking
Supply and Demand Imbalance Indicate Areas for Assessment
About Syneos Health Consulting
Syneos Health Consulting is a management consulting firm specializing in the biopharmaceutical industry and part of Syneos Health. We provide services across a comprehensive range of key areas, including portfolio strategy, brand commercialization and commercial model strategy/planning; medical and regulatory affairs; risk and program management; and pricing, market access and HEOR. Recognized by Forbes magazine as one of America’s Best Management Consulting Firms, we combine industry focus and depth of functional expertise with strong scientific and market knowledge to tackle highly complex business and market challenges, and develop actionable strategies for our clients. For more information, visit www.syneoshealth.com/solutions/consulting or subscribe to our podcast.
Investor Relations Contact: Press/Media Contact:
Ronnie Speight Danielle DeForge
Senior Vice President, Investor Relations Executive Director, External Communications
+1 919 745 2745 +1 202 210 5992